Shooting Cancer

9 11, 2021

NTRK inhibitors, a successful example of a tissue-agnostic approach in anticancer targeted therapy

Diatech Pharmacogenetics2021-11-11T17:46:37+01:00

22 09, 2021

KRAS, a new weapon for the fight against lung cancer and more

Diatech Pharmacogenetics2021-09-28T15:34:42+02:00

30 06, 2021

Lung cancer: molecular markers and new opportunities to treat the early and advanced disease

Diatech Pharmacogenetics2021-07-02T13:53:43+02:00

31 05, 2021

Utility and use of NGS in clinical oncology: ESMO recommendations for patients with metastatic cancers

Diatech Pharmacogenetics2021-05-31T15:21:48+02:00

2 04, 2021

Europe approves the first anti-PD-L1/L1 therapy for patients with MSI-H/dMMR colorectal cancer

Diatech Pharmacogenetics2021-05-04T16:16:16+02:00

25 02, 2021

A breakthrough for the targeted therapy of RET+ tumours with new selective inhibitors

Diatech Pharmacogenetics2021-03-01T15:27:20+01:00

16 12, 2020

Hope of a cure for cholangiocarcinoma coming from FGFR inhibitors

Diatech Pharmacogenetics2021-01-12T14:36:11+01:00

28 09, 2020

Alpelisib and PIK3CA mutations: a new molecular targeted therapy for breast cancer is approved

Diatech Pharmacogenetics2020-10-01T10:04:40+02:00

29 06, 2020

New European recommendations on DPD testing prior to anticancer therapy with fluoropyrimidines

Diatech Pharmacogenetics2020-06-29T18:36:18+02:00

16 04, 2020

A new therapeutic opportunity treatment of NSCLC: the BRAF V600 mutation

Diatech Pharmacogenetics2020-04-17T16:39:14+02:00